| Nanobodies as therapeutics: big opportunities for small antibodies S Steeland, RE Vandenbroucke, C Libert Drug discovery today 21 (7), 1076-1113, 2016 | 433 | 2016 |
| A new venue of TNF targeting S Steeland, C Libert, RE Vandenbroucke International journal of molecular sciences 19 (5), 1442, 2018 | 151 | 2018 |
| Counteracting the effects of TNF receptor‐1 has therapeutic potential in Alzheimer's disease S Steeland, N Gorlé, C Vandendriessche, S Balusu, M Brkic, ... EMBO molecular medicine 10 (4), e8300, 2018 | 104 | 2018 |
| Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1 S Steeland, L Puimège, RE Vandenbroucke, F Van Hauwermeiren, ... Journal of Biological Chemistry 290 (7), 4022-4037, 2015 | 80 | 2015 |
| TNFR1 inhibition with a Nanobody protects against EAE development in mice S Steeland, S Van Ryckeghem, G Van Imschoot, R De Rycke, ... Scientific reports 7 (1), 13646, 2017 | 50 | 2017 |
| Glucocorticoid‐induced microRNA‐511 protects against TNF by down‐regulating TNFR 1 L Puimège, F Van Hauwermeiren, S Steeland, S Van Ryckeghem, ... EMBO molecular medicine 7 (8), 1004-1017, 2015 | 46 | 2015 |
| Topical imiquimod yields systemic effects due to unintended oral uptake L Grine, S Steeland, S Van Ryckeghem, M Ballegeer, S Lienenklaus, ... Scientific reports 6 (1), 20134, 2016 | 43 | 2016 |
| Development and validation of a small single-domain antibody that effectively inhibits matrix metalloproteinase 8 D Demeestere, E Dejonckheere, S Steeland, P Hulpiau, J Haustraete, ... Molecular Therapy 24 (5), 890-902, 2016 | 26 | 2016 |
| A study of cecal ligation and puncture-induced sepsis in tissue-specific tumor necrosis factor receptor 1-deficient mice J Vandewalle, S Steeland, S Van Ryckeghem, M Eggermont, ... Frontiers in Immunology 10, 493331, 2019 | 17 | 2019 |
| Simultaneous inhibition of tumor necrosis factor receptor 1 and matrix metalloproteinase 8 completely protects against acute inflammation and sepsis S Steeland, S Van Ryckeghem, J Vandewalle, M Ballegeer, ... Critical care medicine 46 (1), e67-e75, 2018 | 15 | 2018 |
| Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis JT Guptill, JW Sleasman, S Steeland, M Sips, D Gelinas, H de Haard, ... Autoimmunity 55 (8), 620-631, 2022 | 10 | 2022 |
| Construction of novel bispecific single-domain antibodies (BiSdAbs) with potent antiangiogenic activities X Liu, T Sun, Q Ge, J Zhu Pharmaceutical Fronts 2 (01), e64-e76, 2020 | 6 | 2020 |
| Choroid plexus tumor necrosis factor receptor 1: A new neuroinflammatory piece of the complex Alzheimer’s disease puzzle S Steeland, RE Vandenbroucke Neural Regeneration Research 14 (7), 1144-1147, 2019 | 6 | 2019 |
| Efficient analysis of mouse genome sequences reveal many nonsense variants S Steeland, S Timmermans, S Van Ryckeghem, P Hulpiau, Y Saeys, ... Proceedings of the National Academy of Sciences 113 (20), 5670-5675, 2016 | 6 | 2016 |
| P276 Long-term safety, and efficacy of subcutaneous Efgartigimod PH20 in patients with generalized myasthenia gravis: interim results of ADAPT-SC+ K Musick, J Howard, G Li, T Vu, D Korobko, M Smilowski, L Liu, ... Neuromuscular Disorders 33, S179, 2023 | 1 | 2023 |
| Long-term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Participants with Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC+ Study (P10 … J Howard, Y Li, T Vu, D Korobko, S Steeland, B Van Hoorick, J Podhorna, ... Neurology 102 (17_supplement_1), 6334, 2024 | | 2024 |
| Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis JF Howard Jr, V Bril, T Vu, C Karam, S Peric, JL De Bleecker, H Murai, ... Frontiers in Neurology 14, 1284444, 2024 | | 2024 |
| Efgartigimod demonstrates consistent improvements in patients with generalized myasthenia gravis regardless of prior treatment failures Z Siddiqi, C Rozsa, F Saccá, JL De Bleecker, J Verschuuren, S Hoffmann, ... Journal of the Neurological Sciences 455, 2023 | | 2023 |
| Dose Selection and Clinical Development of Efgartigimod PH20 Subcutaneous in Patients with Generalized Myasthenia Gravis (P1-5.017) G Li, Y Li, T Vu, D Korobko, M Smilowski, L Liu, S Steeland, ... Neurology 100 (17 Supplement 2), 2023 | | 2023 |
| Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Patients with Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC+ Study (P1-5.014) J Howard, G Li, T Vu, D Korobko, M Smilowski, L Liu, S Steeland, ... Neurology 100 (17 Supplement 2), 2023 | | 2023 |
Roosmarijn VandenbrouckeFull Professor, Ghent University and VIBGeverifieerd e-mailadres voor irc.vib-ugent.be
